CM Life Sciences II Inc.
Status: Deal Closed
U=S+W/5
W=S@11.5
| IPO Proceeds, $M | $276.00M |
|---|---|
| IPO Date | Feb 23, 2021 |
| CEO | Eli D. Casdin |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Life sciences |
| IPO Geography | Global |
| Target Company | SomaLogic |
| Deal Announced | Mar 29, 2021 |
| Deal Size, $M | $1,230.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Aug 31, 2021 |
| Amendment Vote | TBD |
| Closing Date | Sep 1, 2021 |
Formerly CMII
SLGC
SLGCW
| Price | 2.08 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on CM Life Sciences II Inc.:
- Structure and cap table
- 8 directors & officers
- 21 filings and events
- 1 underwriters
- 6 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Eli D. Casdin | 47 | Chief Executive Officer and Director |
| Keith A. Meister | 47 | Chairman |
| Brian Emes | 38 | Chief Financial Officer and Secretary |
| Shaun Rodriguez | 42 | Chief Strategy Officer |
| Kevin Conroy | 55 | Director |
| Troy Cox | 56 | Director |
| Jason Kelly | 40 | Director |
| Stephen Quake | 51 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Jefferies | BR | 24,000,000 | units |
| 24,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.